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An efficient strategy for enhancing the lymph node deposition of rapidly drained liposomes from the interstitial injection site is described.
Subcutaneously injected small-sized immuno-poly(ethyleneglycol)-liposomes (immuno-PEG-liposomes), containing 10 mol% mPEG350–
phospholipid and 1 mol% PEG2000–phospholipid in their bilayer and where IgG1 is coupled to the distal end of PEG2000, not only drain rapidly
from the interstitial spaces into the initial lymphatic system, but also accumulate efficiently among the lymph nodes draining the region when
compared with non-PEG-bearing immunoliposomes where IgG is directly coupled to the phospholipid. Liposome deposition among the draining
lymph nodes, however, was further enhanced dramatically following an adjacent subcutaneous injection of a pentameric IgM against the surface
attached IgG molecules (IgM:IgG, 10:1) without compromising vesicle drainage from the interstitium. This is suggested to arise either as a result
of formation of large immuno-aggregates within the lymphatic vessels with subsequent transport to and trapping among the regional lymph nodes
and/or following IgM binding to Fc receptors of the lymph node sinus macrophages forming a platform for subsequent trapping of drained IgG-
coupled liposomes. This lymph node targeting approach may be amenable for the design and surface engineering of any rapidly drained
nanoparticulate system bearing peptides and proteins that can be aggregated with a desired monoclonal pentameric IgM.
© 2007 Elsevier B.V. All rights reserved.Keywords: IgM; Immunoliposome; Lymph node; Lymphatic system; Macrophage; Targeting1. Introduction
Under normal physiological conditions interstitially injected
liposomes are drained into the initial lymphatic system through
patent junctions in the lymphatic capillaries and are then con-
veyed to the regional lymph nodes via the afferent lymph [1].
Within the lymph nodes the drained vesicles are susceptible to
extraction by macrophages of the medullary sinuses and
paracortex; however, littoral cells and polymorphonuclear
granulocytes also play some role in liposome clearance [2].
Such means of vesicle transportation from interstitial sites and
clearance by lymph node scavenger cells has numerous medical
applications to include lymphoscintigraphic tracing, lymph⁎ Corresponding author. Fax: +44 1273 679333.
E-mail address: s.m.moghimi@brighton.ac.uk (S.M. Moghimi).
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doi:10.1016/j.bbamem.2007.08.033node mapping, antimicrobial and antigen delivery, and immune
modulation [1,3,4]. Among the key physicochemical factors
controlling the kinetics of liposome drainage through the
ground substance of the interstitium into the initial lymphatic
system and subsequent macrophage capture are vesicular size,
morphology, and surface characteristics (e.g., electric charge,
hydrophilicity/hydrophobicity, and ligand expression and
density) [1,5–8]. For example, in rats although up to 50% of
the injected dose (footpad injection) of anionic unilamellar
liposomes (size range 90–120 nm) is usually drained into the
lymphatic system within 6–10 h, liposome capture by resident
phagocytic cells of the primary draining lymph node rarely
exceeds 2–3% of this fraction [6]. Liposome clearance by
macrophages of the secondary and tertiary nodes is even less
efficient. Noncaptured vesicles subsequently gain access into
the systemic circulation via thoracic duct and are cleared by
hepatic and splenic macrophages.
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crease the retention and localization of interstitially injected
liposomes among the regional draining nodes. Recently, work
from this laboratory demonstrated that the rate of drainage and
lymphatic distribution (macrophage capture) of interstitially
injected liposomes in rats can be improved dramatically by
simultaneous attachment of a targeting ligand, immunoglobulin-
G (IgG), and inclusion of appropriate methoxypoly(ethylene-
glycol)–phospholipid (mPEG-PL) conjugates into the liposomal
bilayer [9]. However, the extent of both liposome drainage and
macrophage targeting was dependent on the mode of IgG
coupling and surface poly(ethyleneglycol) configuration. For
instance, the lymph node retention (both primary and secondary
nodes) of rapidly drained liposomes of 100–120 nm in size was
not only increased following conjugation of a non-specific IgG
to the distal end of a functionalized PEG2000-PL, but adjusting
the molecular architecture of surface exposed PEG2000 chains to
a “nearly overlapped mushroom/mushroom–brush transition”
regime, yielded vesicles with optimal target-binding capabili-
ty [9]. The latter was achieved by inclusion of 10 mol% of
mPEG350–phospholipid conjugates into the bilayer of IgG-Fig. 1. Schematic representation of immuno-PEG2000-liposome drainage from a sub
lymphatic vessel. Liposomes are injected first into the dorsal surface of rat footpad. Ne
liposome injection. Both IgM and immuno-PEG2000-liposome drain rapidly into th
liposomes encounter each other resulting in the formation of large immuno-aggregatePEG2000-liposomes. This paper demonstrates a further step
towards improving the lymph node retention of IgG-PEG2000-
liposomes through in vivo vesicular aggregation in the lymphatic
vessels with a pentameric IgM (in vivo conversion of “small” to
“big”; Fig. 1) thus enhancing liposome clearance by resident
macrophages via Fc receptors. The principle of this approach
was inspired by a recent observation of Phillips et al. [10] where
it was demonstrated that the retention of interstitially injected
biotin-coated liposomes in draining lymph nodes could be
increased dramatically following an adjacent avidin injection.
2. Materials and methods
2.1. Liposome preparation and characterization
All lipids were from Sigma (Poole, UK) with the exception of -(4′-(4″-
maleimidophenyl)butyroyl)-phosphatidylethanolamine (MPB-PE), mPEG350-
distearoylphosphatidylethanolamine (mPEG350-DSPE) and MPB-PEG2000-
DSPE, which were obtained from Avanti Polar Lipids (Alabaster, AL, USA).
Immunoliposomes were composed of egg phosphatidylcholine (egg PC),
cholesterol (Chol), dicetylphosphate (DCP) and MPB-PE in a molar ratio of
6.925:6.925:1:0.15, respectively. Immuno-PEG-liposomes were composed ofcutaneous injection site followed by IgM-mediated vesicular aggregation in the
xt, pentameric IgMmolecules are injected subcutaneously proximal to the site of
e initial lymphatic vessels. Within the lymphatic vessels IgM molecules and
s. These entities drain into the regional lymph nodes where they become trapped.
Fig. 2. Kinetics of liposome drainage from interstitial spaces of the footpad into
the initial lymphatic system. Radiolabelled liposomes were injected subcutane-
ously into the dorsal surface of the left footpad followed by an adjacent
subcutaneous injection of either buffer (saline) or a pentameric IgM against rat
IgG1 (test IgM) or an irrelevant IgM.
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6.175:6.175:1:1.5:0.15, respectively. Liposomes were prepared by hydrating the
dried lipid film with a buffer (25 mM HEPES, 25 mMMes, 135 mM NaCl), pH
6.7, containing [125I]-poly(vinylpyrrolidone) ([125I]-PVP; Amersham Interna-
tional, Amersham, UK) as an established aqueous space label for in vivo studies
[5,9]. Liposomes were extruded through polycarbonate Nuclopore filters of
100 nm in pore diameter using a high-pressure extruder. Liposome size
distribution was determined by laser light scattering using a Malvern Zetasizer
3000 (Malvern Instruments, Malvern, UK) at 25 °C as described previously [9].
Rat IgG1 (Serotec, UK) was thiolated, using N-succinimidyl-3-(2-pyridyldithio)
proprionate followed by reduction with dithiotheritol (DTT) and characterized
as before [9]. The thiolated antibody was coupled to liposomes via the linker
lipids (MBP-PE or MBP-PEG2000-DSPE). Non-reacted maleimide was blocked
with DTT; free DTT and unbound antibody molecules were removed by passing
the liposome suspension over a Sepharose CL-4B column in HEPES buffer.
Antibody-conjugated liposomes were assayed for their protein content and
phospholipid phosphorus and conjugation results are expressed as microgram
bound antibody per micromoles phospholipid.
2.2. Lymphatic distribution studies
MaleWistar rats (n=3 for each determination), body weight 180±10 g, were
injected subcutaneously into the dorsal surface of the left footpad with [125I]
PVP-encapsulated immunoliposomes or immuno-PEG-liposomes (2.8 μmol
phospholipid) as described previously [9], followed by an adjacent subcutane-
ous injection (50 μl) of either a pentameric IgM (Sigma-Aldrich, UK; produced
in mouse, ascites fluid) against rat IgG1, an irrelevant IgM, or saline proximal to
the site of liposome injection. IgM–IgG interaction was first monitored by
immunodiffusion. The ability of IgM to induce aggregation of IgG1-conjugated
liposomes was confirmed by turbidity measurements.
Animals were sacrificed at various time points post liposome injection and
associated radioactivity was measured in the footpad (whole foot), regional
lymph nodes (the whole popliteal or primary node, iliac or secondary node,
inguinal, and renal nodes), blood (samples taken from tail vein), and whole liver
and spleen, using a gamma counter. Determination of the amount of liposomes
in the blood was made on the assumption of total blood volume per rat of 7.5%
of body weight. Biodistribution data in regional lymph nodes are presented as
percent of injected dose/node±S.E.
3. Results and discussion
Immunoliposomes (IgG attached directly to the phospho-
lipid) were of 126±30 nm (Z-average mean size) with a
polydispersity index of 0.06, bearing 69±16 μg rat IgG1 bound
per μmol phospholipid. Engineered IgG1-PEG2000-liposomes
(IgG is attached to the distal end of PEG2000), containing 10 mol
% mPEG350–phospholipid conjugates in their bilayer, were of
134±31 nm (polydispersity index=0.12) with 62±14 μg IgG1
per μmol phospholipid. In accordance with the earlier report [9]
IgG1-PEG2000-liposomes drained at a faster rate from the
footpad interstitium into the initial lymphatics when compared
with that of immunoliposomes (Fig. 2a and b). This difference
was previously suggested to arise from increased liposome
surface hydrophilicity (due to close association of water mole-
cules with PEG chains), which minimizes vesicle interaction
with the ground substance of the interstitium [9]. Popliteal node
(1° node) drains the footpad through lymph vessels; efferent
popliteal trunks follow to a retroperitoneal lymphatic plexus
dorsal to the iliac vessels and themain trunk continues to the iliac
nodes (2° node). Therefore, we next examined liposome
deposition in both popliteal and iliac nodes. Both popliteal and
iliac node localization of IgG1-PEG2000-liposomes was superior
to that of immunoliposomes at all time points (Fig. 3), whichmay be attributed to their faster drainage from the interstitium,
particularly within the first few hours of injection, and hence less
exposure time to Fc receptor-bearing interstitial phagocytes. For
example, at 24-h popliteal and iliac nodes retained 6.3±0.9%
and 5.7±0.2% of injected dose of IgG1-PEG2000-liposomes,
respectively, whereas the corresponding values for immunolipo-
somes were 1.9±0.2% and 1.4±0.3% of injected dose,
respectively.
Although particulate systems and vesicles N150 nm are more
susceptible to macrophage recognition and clearance than their
smaller counterparts, they move very slowly from the interstitial
injection site into the initial lymphatics; the drainage may often
take periods of days depending on particle surface hydropho-
bicity [1,3,11,12]. However, this slow transit may induce local
inflammation and renders particles and liposomes susceptible to
macrophage clearance at the injection site thus limiting their
direct transport to the lymphatic system [1,11]. Therefore, for
lymphatic transport smaller vesicles are of preferred choice. In
order to further enhance lymph node retention of the rapidly
drained small-sized immunoliposomes and IgG1-PEG2000-
liposomes we induced vesicle aggregation within the lymphatic
vessels and lymph nodes. This was achieved by an adjacent
subcutaneous injection of a monoclonal pentameric IgM against
the rat IgG1 (IgM:IgG, 10:1) proximal to the site of liposome
injection. Firstly, IgM injection had no significant effect on
liposome drainage at 2 and 6 h, irrespective of the antibody-
conjugated liposome type and despite occurrence of some mild
inflammatory reactions, when compared with the corresponding
Fig. 4. Liposome levels among the organs of the reticuloendothelial system,
RES (liver + spleen) and in the blood at 24 h post interstitial injection. The open
and closed columns represent animals that received an adjacent subcutaneous
injection of an irrelevant IgM (control) and test IgM, respectively.
Fig. 3. The extent of liposome retention in 1° (popliteal) and 2° (iliac) lymph nodes. The open and closed columns represent immunoliposomes and IgG1-PEG2000-
liposomes, respectively. ⁎pb0.05, ⁎⁎pb0.01 compared with the irrelevant IgM administration.
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IgM injection), whereas at 24 h significantly more liposomes
were retained at the injection site (Fig. 2). The latter may
correspond to the formation of some local immuno-aggregates
and initiation of further inflammatory reactions. Liposome
retention in the popliteal node (Fig. 3a, c and e) was increased
dramatically at all time points in animals that received
monoclonal IgM injection when compared with that of the
corresponding controls (saline and irrelevant IgM injections).
The effect, however, was more profound with IgG1-PEG2000-
liposomes than that of immunoliposomes, which may be
ascribed to their faster drainage from the injection site thus
encountering more IgM (which also drains rapidly into the
lymphatic system) within the lymphatic vessels. Remarkably,
the extent of IgG1-PEG2000-liposomes in the iliac node (Fig. 3b,
d and f) was also increased by the monoclonal IgM, particularly
at 24 h; this presumably corresponds to trapping of smaller
immuno-aggregates that escaped filtration at the popliteal node
level. The described strategy therefore enhances liposome
retention among a chain of draining lymph nodes (liposome
retention in both inguinal and renal nodes was also increased;
data not shown). The enhanced lymph node retention of lipo-
somes following monoclonal IgM treatment was also associated
with lower levels of vesicle capture by phagocytic elements of
the liver and the spleen when compared with control (irrelevant
antibody, Fig. 4).
When monoclonal IgM and antibody-conjugated liposomes
were mixed prior to subcutaneous injection, liposomes drained
poorly into the lymphatic system (more than 80% of vesicles
remained at injection site at 24 h post injection) and total noderetention (popliteal and iliac nodes) did not exceed 3.5% of the
injected dose. On the basis of these observations we suggest that
the enhanced lymph node retention of IgG1-PEG2000-liposomes
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their fast drainage from the injection site but also as a result of
formation of some liposome–IgM aggregates presumably within
the lymphatic vessels, which become trapped in the next encoun-
tered lymph node and/or in lymph node sinuses. With regard to
the latter speculation it is possible that the rapidly drained IgM
molecules may bind to macrophage Fc receptors in the draining
lymph node sinuses thus forming platforms for subsequent
trapping of IgG-coupled liposomes. Although IgM is not cationic,
this proposed mechanism is rather similar to the previously
described avidin/biotin-liposome system, where on the basis of
intracavitary injections it was concluded that the positively
charged avidin may bind to the negatively charged surface of
endothelial cells in the lymph nodes and subsequently act as a
platform for trapping of drained biotin-tagged liposomes [13,14].
In the hindlimb and forelimb, gentle massage of the area
drained by the lymphatic vessels results in an increased flow of
lymph [15]. Thus local massaging may accelerate the formation
of liposome–IgM aggregates thereby further enhancing their
lymph node retention, but this strategy awaits further investi-
gation. Nevertheless, the described lymph node targeting
approach may be amenable for design and surface engineering
of any rapidly drained nanoparticulate system bearing peptides
and proteins that can be aggregated with a desired monoclonal
pentameric IgM.
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